Render Target: STATIC
Render Timestamp: 2024-07-26T10:55:54.277Z
1% for the planet logo
PDP - Template Name: siRNA
PDP - Template ID: *******aa36529

SignalSilence® Aldolase A siRNA I #8966

This product is discontinued

Inquiry Info. # 8966

Please see our recommended alternatives.

    Supporting Data

    REACTIVITY H
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    CST recommends transfection with 100 nM SignalSilence® Aldolase A siRNA I 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.

    Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.

    Storage

    SignalSilence® siRNA is supplied in RNAse-free water. Aliquot and store at -20ºC.

    Product Description

    SignalSilence® Aldolase A siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit aldolase A expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.

    Quality Control

    Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.

    Background

    Aldolase (fructose bisphosphate aldolase), a glycolytic enzyme, catalyzes the conversion of fructose 1, 6-bisphosphate to 3-phosphoglyceraldehyde. This ubiquitous enzyme is present as three different isozymes: aldolase A, aldolase B, and aldolase C. Research studies suggest that aldolase A expression potentially differentiates between nonneoplastic liver diseases and hepatocarcinoma (1). Furthermore, investigators have shown that changes in aldolase B gene expression levels have been observed in certain patients with this primary tumor (2,3).

    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    SignalSilence is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.